Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix, Versus MenC-CRM197 Vaccine With Hiberix and Priorix in Toddlers Primed With Hib But Not MenC and to Evaluate Persistence up to 5 Years After Vaccination.

Trial Profile

Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix, Versus MenC-CRM197 Vaccine With Hiberix and Priorix in Toddlers Primed With Hib But Not MenC and to Evaluate Persistence up to 5 Years After Vaccination.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; Hib vaccine conjugate; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate
  • Indications Haemophilus infections; Measles; Meningococcal group C infections; Mumps; Rubella
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Mar 2011 Primary endpoint 'Antibody-levels' has been met
    • 05 Nov 2009 Status changed from completed to active, no longer recruiting.
    • 27 Oct 2009 Planned end date (Dec 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top